Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 dec 2007 - 06:43
Statutaire naam
Pharming Group N.V.
Titel
PHARMING STARTS COLLABORATION WITH SOLVAY AND ACADEMIC GROUPS ON PARKINSON AND ALZHEIMER DISEASE
Bericht
Leiden, The Netherlands, December 17, 2007. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage BV (“DNage”) will participate in a TI Pharma consortium that brings together leading researchers from academia and industry in the field of neurodegeneration and drug development. The collaboration exemplifies Pharming’s strategy to expand its research engine and to strengthen its product pipeline.
Under the terms of the agreement, the two commercial partners DNage and Solvay Pharmaceuticals BV will collaborate with eight top class academic groups to embark on a four year project with a total budget of € 6.8 million. The program will be supported by TI Pharma who will contribute approximately € 3.4 million with the remaining costs to be divided over the ten partners in the consortium.
The project entails a large-scale, groundbreaking effort to identify target molecules that can serve as the basis for the development of novel medicines for Parkinson and Alzheimer disease. DNage will use its accelerated ageing mouse models that are based on its intellectual property linking DNA damage to the development of ageing diseases. These animal models provide excellent opportunities and unique tools for in-depth analysis of the onset and progression of neurodegeneration and moreover, allow pharmaceutical intervention studies at any stage of neurodegeneration. The consortium will further have access to a large collection of human Alzheimer’s and Parkinson’s brain tissue, and through integration of multidisciplinary expertise and innovative technologies, DNage and partners aim to identify dysregulated genes and proteins that may serve as potential drug targets or biomarkers relevant for these serious diseases.
Alzheimer disease is the most common form of dementia and is marked by progressive memory loss and decline in mental functions while Parkinson’s is a neurological disorder that gradually affects muscul
Datum laatste update: 05 februari 2025